The findings, published online December 1 in Cancer Research, a journal of the American Association for Cancer Research, could lead to a simple blood test to detect lung cancer in its earliest phases, when it can be most successfully treated.
Wistar investigators Louise C. Showe, Ph.D., and Michael K. Showe Ph.D., and colleagues examined gene expression profiles in blood samples from more than 200 patients with lung cancer or other, non-malignant, lung diseases. Focusing on non-small cell lung cancer (NSCLC), and the large at-risk population of smokers and ex-smokers, the researchers sought to determine whether lung tumors—even at the earliest stages—leave a gene expression signature in circulating blood cells. Recent studies have shown that in some late-stage cancers, an immune system response can be detected in the blood which can contain information on responsiveness to therapy or identify markers associated with prognosis.
For the study, peripheral blood was drawn from lung disease patients at the University of Pennsylvania Medical Center (Penn) and the New York University School of Medicine from 2003 through 2007, and the gene expression patterns in the samples were analyzed at Wistar. The team was able to identify a 29-gene “signature” that separated 137 patients with NSCLC tumors from 91 patient controls with non-malignant lung conditions, with 86 percent accuracy. Immune cells, which normally function to fight tumors, showed certain changes in the patients with malignant tumors that distinguished them from those of patients with other lung diseases such as chronic obstructive pulmonary disease or emphysema and patients with benign lung nodules.
When 18 NSCLC patients had peripheral blood drawn before surgery and again two to five months after their tumors were surgically removed, 13 of the samples showed a decrease in or complete disappearance of the tumor gene signature present in the pre-surgery samples after tumor removal. This finding demonstrates that the tumor presence can be communicated to the peripheral immune system and this signal can be detected in the gene expression patterns in peripheral blood.
Lung cancer is the most commonly occurring cancer in both men and women in the United States, accounting for 162,000 deaths in 2008, more than any other cancer. Early diagnosis followed by surgery presently is the most effective treatment for NSCLC, which accounts for 75 percent of lung tumors. Detecting cancer at its earliest stages would greatly improve the likelihood of survival; however, no simple and accurate screening test such as mammography for breast cancer or colonoscopy for colon cancer exists for lung cancer. In addition, early-stage lung cancers show few symptoms and tend to spread rapidly before they are found.
With further study, the findings may serve as the basis for developing a simpler screening test for lung cancer. “People routinely get blood taken at their doctor’s offices, for cholesterol levels, diabetes, and other standard tests, so why not utilize this method to screen for other conditions such as the risk of developing lung cancer?” says Louise Showe, a professor in Wistar’s Molecular and Cellular Oncology and Immunology programs and director of its genomics facility. “Such a test could be especially useful for remote areas where typically technologies that are used in urban centers are not available. In addition, this test could be useful in a clinical setting to help to decide whether a small tumor detected on an x-ray is likely to be malignant.”
The team is working to develop a simpler method for collecting and processing blood samples for analysis. In addition, the clinical collaborators are gathering follow-up data from patients which will be used to analyze the data for signatures of recurrence and/or response to therapy. The researchers are also conducting additional analyses to further explore the basis for the changes in the peripheral immune system after tumor removal.
The lead author on the Cancer Research publication is Michael K. Showe, Ph.D. Other researchers involved in the study from The Wistar Institute include Andrew V. Kossenkov, Ph.D.; Elena V. Nikonova, M.D.; Celia Chang, Ph.D.; Calen Nichols and David A. Speicher, Ph.D. Collaborators from the University of Pennsylvania School of Medicine include Steven M. Albelda, M.D.; Anil Vachani, M.D.; John Kucharczuk, M.D.; Bao Tran and Elliot Wakeam and from the New York University School of Medicine William N. Rom, M.D., M.P.H.; and Ting an Yie, M.S.
This study was support by Pennsylvania Department of Health (PA DOH) Tobacco Settlement Grants, the PA DOH Commonwealth Universal Research Enhancement Program, the National Cancer Institute, and a Wistar Cancer Center Support Grant.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today’s Discoveries – Tomorrow’s Cures. On the Web at www.wistar.org.
Michael K. Showe | Newswise Science News
GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University
Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.
Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...
In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...
13.04.2018 | Event News
12.04.2018 | Event News
09.04.2018 | Event News
20.04.2018 | Physics and Astronomy
20.04.2018 | Interdisciplinary Research
20.04.2018 | Physics and Astronomy